1. Home
  2. FSTR vs PLX Comparison

FSTR vs PLX Comparison

Compare FSTR & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo L.B. Foster Company

FSTR

L.B. Foster Company

HOLD

Current Price

$28.09

Market Cap

280.8M

Sector

Industrials

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$2.11

Market Cap

230.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSTR
PLX
Founded
1902
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.8M
230.0M
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
FSTR
PLX
Price
$28.09
$2.11
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$32.00
$12.00
AVG Volume (30 Days)
25.9K
1.1M
Earning Date
03-03-2026
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.69
N/A
Revenue
$540,009,000.00
$52,744,000.00
Revenue This Year
$5.12
$37.52
Revenue Next Year
$2.78
$1.25
P/E Ratio
$40.58
N/A
Revenue Growth
1.74
N/A
52 Week Low
$17.16
$1.34
52 Week High
$32.63
$3.19

Technical Indicators

Market Signals
Indicator
FSTR
PLX
Relative Strength Index (RSI) 44.53 32.08
Support Level $27.26 $2.03
Resistance Level $29.43 $2.14
Average True Range (ATR) 1.03 0.12
MACD -0.02 -0.10
Stochastic Oscillator 53.37 7.37

Price Performance

Historical Comparison
FSTR
PLX

About FSTR L.B. Foster Company

L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: